Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.

Pino MS, Milella M, Gelibter A, Sperduti I, De Marco S, Nuzzo C, Bria E, Carpanese L, Ruggeri EM, Carlini P, Cognetti F.

Oncology. 2009;76(4):254-61. doi: 10.1159/000205388. Epub 2009 Feb 26.

PMID:
19246950
[PubMed - indexed for MEDLINE]
2.

Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.

Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ.

Am J Clin Oncol. 2009 Aug;32(4):348-52. doi: 10.1097/COC.0b013e31818c08ff.

PMID:
19363436
[PubMed - indexed for MEDLINE]
3.

Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.

Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA.

Am J Clin Oncol. 2012 Oct;35(5):411-7.

PMID:
21552099
[PubMed - indexed for MEDLINE]
4.

Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.

Murad AM, Guimarães RC, Aragão BC, Rodrigues VH, Scalabrini-Neto AO, Padua CA, Moore FC.

Am J Clin Oncol. 2003 Apr;26(2):151-4.

PMID:
12714886
[PubMed - indexed for MEDLINE]
5.

Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.

Milella M, Gelibter A, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Malaguti P, Pellicciotta M, Terzoli E, Cognetti F.

Cancer. 2004 Jul 1;101(1):133-8.

PMID:
15221998
[PubMed - indexed for MEDLINE]
Free Article
6.

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.

Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS.

J Clin Oncol. 2007 Oct 20;25(30):4787-92.

PMID:
17947726
[PubMed - indexed for MEDLINE]
Free Article
7.

Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.

Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhöfer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B.

Br J Cancer. 2008 Jan 29;98(2):309-15. doi: 10.1038/sj.bjc.6604178. Epub 2008 Jan 8.

PMID:
18182984
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.

Santini D, Virzi V, Vasile E, Vincenzi B, Catalano V, Graziano F, Masi G, Bronte G, Russo A, Falcone A, Tonini G.

Oncology. 2012;82(2):75-82. doi: 10.1159/000329079. Epub 2012 Feb 7.

PMID:
22327844
[PubMed - indexed for MEDLINE]
9.

Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.

Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung JB, Park MS, Yu JS, Yoon DS.

Cancer. 2005 Dec 15;104(12):2753-8.

PMID:
16294346
[PubMed - indexed for MEDLINE]
Free Article
10.

Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.

Dragovich T, Burris H 3rd, Loehrer P, Von Hoff DD, Chow S, Stratton S, Green S, Obregon Y, Alvarez I, Gordon M.

Am J Clin Oncol. 2008 Apr;31(2):157-62. doi: 10.1097/COC.0b013e31815878c9.

PMID:
18391600
[PubMed - indexed for MEDLINE]
11.

Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.

Saif MW, Syrigos K, Penney R, Kaley K.

Anticancer Res. 2010 Jul;30(7):2905-9.

PMID:
20683031
[PubMed - indexed for MEDLINE]
12.

Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.

Boeck S, Wilkowski R, Bruns CJ, Issels RD, Schulz C, Moosmann N, Laessig D, Haas M, Golf A, Heinemann V.

Oncology. 2007;73(3-4):221-7. doi: 10.1159/000127413. Epub 2008 Apr 17.

PMID:
18424886
[PubMed - indexed for MEDLINE]
13.

Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.

Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK.

Cancer Chemother Pharmacol. 2007 Aug;60(3):321-8. Epub 2006 Dec 2.

PMID:
17143602
[PubMed - indexed for MEDLINE]
14.

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

Köhne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Müller L, Janssens J, Bokemeyer C, Reimer P, Link H, Späth-Schwalbe E, Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E.

Ann Oncol. 2008 May;19(5):920-6. Epub 2007 Dec 6.

PMID:
18065406
[PubMed - indexed for MEDLINE]
Free Article
15.

Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.

Kim ST, Lee J, Park SH, Lee JK, Lee KT, Lee KH, Heo JS, Choi SH, Choi DW, Park YS, Lim HY, Kang WK, Jang KT, Park HC, Lim do H, Park JO.

Am J Clin Oncol. 2012 Oct;35(5):432-8.

PMID:
21606820
[PubMed - indexed for MEDLINE]
16.

A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.

El-Rayes BF, Zalupski MM, Shields AF, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Adsay V, Philip PA.

Invest New Drugs. 2005 Dec;23(6):583-90.

PMID:
16034525
[PubMed - indexed for MEDLINE]
17.

Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.

Steinbild S, Arends J, Medinger M, Häring B, Frost A, Drevs J, Unger C, Strecker R, Hennig J, Mross K.

Onkologie. 2007 Dec;30(12):629-35. Epub 2007 Nov 30.

PMID:
18063875
[PubMed - indexed for MEDLINE]
18.

Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.

Li J, Merl M, Lee MX, Kaley K, Saif MW.

Expert Opin Drug Saf. 2010 Mar;9(2):207-13. doi: 10.1517/14740330903555181.

PMID:
20095915
[PubMed - indexed for MEDLINE]
19.

Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.

Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, Um SH, Kim JS, Kim YH.

Am J Clin Oncol. 2000 Aug;23(4):425-8.

PMID:
10955877
[PubMed - indexed for MEDLINE]
20.

Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study.

Gunnlaugsson A, Anderson H, Lind P, Glimelius B, Johnsson A.

Radiother Oncol. 2010 Jun;95(3):292-7. doi: 10.1016/j.radonc.2010.04.004. Epub 2010 May 5.

PMID:
20451275
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk